Oct. 2 at 11:02 AM
$EVH There's one thing I really don't understand. Evolent Health is already a company that has improved gross profit and thus significantly reduced losses. In fact, today it's making a slight profit, which is then wiped out by negative interest on debt, etc.
The positive thing is that Evolent continues to sign new contracts and has announced a target of
$1 billion in new revenue in 2026—exceptional numbers. Now all we have to do is wait for the next quarterly results, consider new agreements, and see Evolent at a high level.
$20-
$30 per share? As soon as there are stable net profits, it will be a sure thing!
